Literature DB >> 9652744

Tec is involved in G protein-coupled receptor- and integrin-mediated signalings in human blood platelets.

Y Hamazaki1, H Kojima, H Mano, Y Nagata, K Todokoro, T Abe, T Nagasawa.   

Abstract

Tec is a non-receptor type tyrosine kinase which is tyrosine phosphorylated and activated upon stimulation of hematopoietic cells with various cytokines. The role of Tec in G protein-coupled receptor- and integrin-mediated signalings has not been elucidated. We therefore investigated the regulation of Tec in human blood platelets. Tec was rapidly tyrosine phosphorylated in response to platelet agonists which activate G protein-coupled receptors such as thromboxane A2 analog (U46619), thrombin, and thrombin receptor activating peptide (TRAP). TRAP-induced phosphorylation in Tec was significantly reduced under the conditions which abrogate fibrinogen binding to GP IIb-IIIa and subsequent platelet aggregation. However, TRAP induced significant levels of the phosphorylation even under these conditions and also in thrombasthenic platelets which lack functional GP IIb-IIIa molecules, suggesting that activation of G-protein-coupled receptor causes the phosphorylation. To clarify whether integrin engagement by itself causes the phosphorylation in Tec, we examined the state of the phosphorylation in platelets activated by integrin engagement. Platelet adhesion to immobilized fibrinogen or collagen induced significant levels of the phosphorylation. Furthermore, Tec was translocated to cytoskeleton in response to TRAP in a manner dependent on platelet aggregation, suggesting that Tec can be a component of integrin-mediated signalings. These results collectively indicate that Tec is involved in G protein-coupled receptor- and integrin-mediated signalings in human blood platelets.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652744     DOI: 10.1038/sj.onc.1201799

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Regulation and physiological functions of G12/13-mediated signaling pathways.

Authors:  Nobuchika Suzuki; Nicole Hajicek; Tohru Kozasa
Journal:  Neurosignals       Date:  2009-02-12

Review 2.  Signalling mechanisms of RhoGTPase regulation by the heterotrimeric G proteins G12 and G13.

Authors:  Tohru Kozasa; Nicole Hajicek; Christina R Chow; Nobuchika Suzuki
Journal:  J Biochem       Date:  2011-08-26       Impact factor: 3.387

Review 3.  Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.

Authors:  Jon E Arnason; Jennifer R Brown
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

4.  Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase.

Authors:  K Ohya; S Kajigaya; A Kitanaka; K Yoshida; A Miyazato; Y Yamashita; T Yamanaka; U Ikeda; K Shimada; K Ozawa; H Mano
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

5.  Tec kinases regulate actin assembly and cytokine expression in LPS-stimulated human neutrophils via JNK activation.

Authors:  Rachel L Zemans; Patrick G Arndt
Journal:  Cell Immunol       Date:  2009-04-23       Impact factor: 4.868

6.  Galpha 12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF.

Authors:  Nobuchika Suzuki; Susumu Nakamura; Hiroyuki Mano; Tohru Kozasa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-06       Impact factor: 11.205

7.  Tec/Bmx non-receptor tyrosine kinases are involved in regulation of Rho and serum response factor by Galpha12/13.

Authors:  J Mao; W Xie; H Yuan; M I Simon; H Mano; D Wu
Journal:  EMBO J       Date:  1998-10-01       Impact factor: 11.598

Review 8.  Critical molecular pathways in CLL therapy.

Authors:  Gerardo Ferrer; Emili Montserrat
Journal:  Mol Med       Date:  2018-03-15       Impact factor: 6.354

9.  Regulated aggregative multicellularity in a close unicellular relative of metazoa.

Authors:  Arnau Sebé-Pedrós; Manuel Irimia; Javier Del Campo; Helena Parra-Acero; Carsten Russ; Chad Nusbaum; Benjamin J Blencowe; Iñaki Ruiz-Trillo
Journal:  Elife       Date:  2013-12-24       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.